Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alnylam Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $37,716 Mil.
Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $1,125 Mil. Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 2.94%.
The historical rank and industry rank for Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LTS:0HD2'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17.24 Med: -4.36 Max: 4.26
Current: 3.93
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Alnylam Pharmaceuticals was 4.26%. The lowest was -17.24%. And the median was -4.36%.
LTS:0HD2's Earnings Yield (Joel Greenblatt) % is ranked better than 88.58% of 1340
companies
in the Biotechnology industry
Industry Median: -10.155
vs LTS:0HD2: 3.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Alnylam Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Alnylam Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Alnylam Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Alnylam Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,125 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 2.94% mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Earnings Yield (Joel Greenblatt) % of 2.94% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alnylam Pharmaceuticals and its competitors. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #153 out of 1340 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Alnylam Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Alnylam Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % is 2.94%. Based on the distribution chart, Alnylam Pharmaceuticals ranks #153 out of 1340 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to ONC and RVMD?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #153 out of 1340 companies for Earnings Yield (Joel Greenblatt) %. This places Alnylam Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 2.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $526.78, compared to a current price of $230.14 — trading 56.3% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 2.94%. Alnylam Pharmaceuticals' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Earnings Yield (Joel Greenblatt) % is 2.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $230.14 is trading 56.3% below its estimated GF Value™ of $526.78.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Earnings Yield (Joel Greenblatt) %: 2.94%
GF Value™: $526.78 vs. price of $230.14 (56.3% below fair value)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
68GF Score
Get the complete analysis for LTS:0HD2
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
